Sunday 31 August 2014

Drug Shows Promise for Subset of Patients With Stage III Colon Cancer

A subset of patients with stage III colon cancer when treated with irinotecan-based therapy had improved survival rates. This is according to a new study in emGastroenterology/emsup1/sup, the official journal of the American Gastroenterological Association. When added to the standard chemotherapy treatment - fluorouracil and leucovorin - adjuvant irinotecan therapy improved overall survival rates for patients with the CpG island methylator phenotype ...

via Medindia Health News More READ

No comments:

Post a Comment